Peptide transporter (TAP-1 and TAP-2)-independent endogenous processing of Epstein-Barr virus (EBV) latent membrane protein 2A: implications for cytotoxic T-lymphocyte control of EBV-associated malignancies
暂无分享,去创建一个
D J Moss | R Khanna | S. L. Silins | S. Burrows | R. Khanna | D. Moss | S R Burrows | S L Silins
[1] J. Yewdell,et al. TAP (transporter associated with antigen processing)-independent presentation of endogenously synthesized peptides is enhanced by endoplasmic reticulum insertion sequences located at the amino- but not carboxyl-terminus of the peptide. , 1994, Journal of immunology.
[2] S. Burrows,et al. Five new cytotoxic T cell epitopes identified within Epstein-Barr virus nuclear antigen 3. , 1994, The Journal of general virology.
[3] P. Chomez,et al. A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. , 1991, Science.
[4] P. Cresswell,et al. Endogenously synthesized peptide with an endoplasmic reticulum signal sequence sensitizes antigen processing mutant cells to class I- restricted cell-mediated lysis , 1991, The Journal of experimental medicine.
[5] M. Doyle,et al. Biological activity of recombinant human interleukin-2 produced in Escherichia coli. , 1984, Science.
[6] D. Pardoll. Immunotherapy with cytokine gene‐transduced tumor cells: the next wave in gene therapy for cancer , 1992, Current opinion in oncology.
[7] Maria L. Wei,et al. HLA-A2 molecules in an antigen-processing mutant cell contain signal sequence-derived peptides , 1992, Nature.
[8] C. Meijer,et al. Differences in MHC and TAP-1 expression in cervical cancer lymph node metastases as compared with the primary tumours. , 1994, British Journal of Cancer.
[9] R. Siliciano,et al. Transporter-independent processing of HIV-1 envelope protein for recognition by CD8+ T cells , 1993, Nature.
[10] S. Burrows,et al. Endoplasmic reticulum signal sequence facilitated transport of peptide epitopes restores immunogenicity of an antigen processing defective tumour cell line. , 1994, International immunology.
[11] S. Burrows,et al. Cytotoxic T-cell clones discriminate between A- and B-type Epstein-Barr virus transformants , 1988, Nature.
[12] R. Siliciano,et al. An epitope-selective, transporter associated with antigen presentation (TAP)-1/2-independent pathway and a more general TAP-1/2-dependent antigen-processing pathway allow recognition of the HIV-1 envelope glycoprotein by CD8+ CTL. , 1995, Journal of immunology.
[13] B. Walker,et al. Presentation of endogenous peptides to MHC class I-restricted cytotoxic T lymphocytes in transport deletion mutant T2 cells. , 1993, Journal of immunology.
[14] S. Burrows,et al. The specificity of recognition of a cytotoxic T lymphocyte epitope , 1992, European journal of immunology.
[15] P. Cresswell,et al. Impaired assembly and transport of HLA‐A and ‐B antigens in a mutant TxB cell hybrid. , 1986, The EMBO journal.
[16] E. Kieff,et al. A second Epstein-Barr virus membrane protein (LMP2) is expressed in latent infection and colocalizes with LMP1 , 1990, Journal of virology.
[17] F. Momburg,et al. Poor loading of major histocompatibility complex class II molecules with endogenously synthesized short peptides in the absence of invariant chain , 1995, European journal of immunology.
[18] D. Moss,et al. T cell recognition of Epstein-Barr virus associated lymphomas. , 1992, Cancer surveys.
[19] J. Trowsdale,et al. Restoration of endogenous antigen processing in Burkitt's lymphoma cells by Epstein‐Barr virus latent membrane protein‐1: coordinate up‐regulation of peptide transporters and HLA‐class I antigen expression , 1995, European journal of immunology.
[20] A. Mullbacher,et al. Recombinant expression of vaccinia virus‐encoded TAP1 and TAP2 promotes MHC class I‐restricted antigen presentation in a Syrian hamster cell line , 1995, Immunology and cell biology.
[21] E. Kieff,et al. Localization of Epstein-Barr virus cytotoxic T cell epitopes using recombinant vaccinia: implications for vaccine development , 1992, The Journal of experimental medicine.
[22] W. Bodmer,et al. MHC antigens and cancer: Implications for T-cell surveillance , 1992, Current Biology.
[23] R. Doms,et al. Regulation of protein export from the endoplasmic reticulum. , 1988, Annual review of cell biology.
[24] T. Tursz,et al. Consistent transcription of the Epstein-Barr virus LMP2 gene in nasopharyngeal carcinoma , 1992, Journal of virology.
[25] S. Burrows,et al. Presentation of endogenous viral peptide epitopes by anti-CD40 stimulated human B cells following recombinant vaccinia infection. , 1993, Journal of immunological methods.
[26] T. Braciale,et al. Antigen presentation: structural themes and functional variations. , 1991, Immunology today.
[27] Robert DeMars,et al. Restored expression of major histocompatibility class I molecules by gene transfer of a putative peptide transporter , 1991, Nature.
[28] L. Lanier,et al. CD28 interaction with B7 costimulates primary allogeneic proliferative responses and cytotoxicity mediated by small, resting T lymphocytes , 1992, The Journal of experimental medicine.
[29] F. Khanim,et al. HLA A2.1-restricted cytotoxic T cells recognizing a range of Epstein-Barr virus isolates through a defined epitope in latent membrane protein LMP2 , 1993, Journal of virology.
[30] W. Kast,et al. Protection against lethal Sendai virus infection by in vivo priming of virus-specific cytotoxic T lymphocytes with a free synthetic peptide. , 1991, Proceedings of the National Academy of Sciences of the United States of America.
[31] A. Townsend,et al. Restoration of antigen presentation to the mutant cell line RMA-S by an MHC-linked transporter , 1991, Nature.
[32] D. Hunt,et al. Direct analysis of tumor-associated peptide antigens. , 1994, Current opinion in immunology.
[33] I. Ernberg,et al. Variable expression of latent membrane protein in nasopharyngeal carcinoma can be related to methylation status of the Epstein-Barr virus BNLF-1 5'-flanking region , 1991, Journal of virology.
[34] L. Young,et al. Epstein-Barr virus and Hodgkin's disease: transcriptional analysis of virus latency in the malignant cells , 1993, The Journal of experimental medicine.
[35] S. Burrows,et al. EBV peptide epitope sensitization restores human cytotoxic T cell recognition of Burkitt's lymphoma cells. Evidence for a critical role for ICAM-2. , 1993, Journal of Immunology.
[36] A. Worth,et al. Characterization of two Epstein‐Barr virus epitopes restricted by HLA‐B7 , 1995, European journal of immunology.
[37] R. Henderson,et al. HLA-A2.1-associated peptides from a mutant cell line: a second pathway of antigen presentation. , 1992, Science.
[38] J. Yewdell,et al. Identification of human cancers deficient in antigen processing , 1993, The Journal of experimental medicine.
[39] E. Kieff,et al. Expression of Epstein-Barr virus nuclear antigens in anti-IgM-stimulated B cells following recombinant vaccinia infection and their recognition by human cytotoxic T cells. , 1991, Immunology.
[40] J. Yewdell,et al. Brefeldin A specifically inhibits presentation of protein antigens to cytotoxic T lymphocytes. , 1989, Science.
[41] S. Beck,et al. Sequences encoded in the class II region of the MHC related to the 'ABC' superfamily of transporters , 1990, Nature.
[42] J. Yewdell,et al. Trimming of antigenic peptides in an early secretory compartment , 1994, The Journal of experimental medicine.
[43] M. Epstein,et al. Cell-mediated immunosurveillance mechanisms and the pathogenesis of Burkitt's lymphoma. , 1985, IARC scientific publications.
[44] G. Freeman,et al. Constitutive expression of B7 restores immunogenicity of tumor cells expressing truncated major histocompatibility complex class II molecules. , 1993, Proceedings of the National Academy of Sciences of the United States of America.
[45] R. Demars,et al. A gene in the human major histocompatibility complex class II region controlling the class I antigen presentation pathway , 1990, Nature.